High Aldosterone Symptoms: When to See a Doctor

What High Aldosterone Actually Feels Like

Most people with primary aldosteronism (PA) do not realize their symptoms point to an adrenal problem. The excess aldosterone drives sodium retention and potassium wasting in the kidneys, producing a cluster of complaints that overlap with common conditions like stress, aging, or simple dehydration.

The most frequent presentation is blood pressure that refuses to normalize. A 2017 cross-sectional analysis in the Annals of Internal Medicine found that PA prevalence rose from 3.9% in Stage 1 hypertension to 11.8% in Stage 3, and reached 22% among patients with treatment-resistant hypertension 1. Patients often describe morning headaches and a persistent feeling of pressure behind the eyes that standard antihypertensives do not relieve. Blood pressure readings may swing unpredictably, with systolic values exceeding 160 mmHg even on three-drug regimens.

Potassium depletion produces the second wave of symptoms. Muscle cramps that wake you at night, generalized weakness that worsens after exercise, tingling in the hands and feet, and heart palpitations all trace back to hypokalemia. A serum potassium below 3.5 mEq/L appears in roughly 9 to 37% of PA patients, though the Endocrine Society's 2016 Clinical Practice Guideline emphasizes that most PA patients are normokalemic at diagnosis 2. Waiting for low potassium to appear before suspecting PA misses the majority of cases.

Polyuria and nocturia round out the pattern. Chronic hypokalemia impairs the kidney's ability to concentrate urine, so patients may produce 3 to 4 liters of dilute urine per day and wake two or three times nightly to void. Thirst follows. These symptoms frequently get attributed to diabetes or benign prostatic hyperplasia in men, delaying correct diagnosis by years.

Why High Aldosterone Causes More Damage Than High Blood Pressure Alone

Excess aldosterone is not simply another route to elevated blood pressure. It inflicts direct organ damage independent of the pressure load itself.

A landmark 2004 study by Milliez and colleagues published in the European Journal of Endocrinology compared 124 PA patients with 465 essential hypertension controls matched for age, sex, and blood pressure level. PA patients had significantly higher rates of stroke (12.9% vs. 3.4%), myocardial infarction (4.0% vs. 0.6%), and atrial fibrillation (7.3% vs. 0.6%) 3. The cardiovascular risk was disproportionate to what their blood pressure numbers alone would predict. Aldosterone activates mineralocorticoid receptors in the heart, blood vessels, and kidneys, triggering inflammation, fibrosis, and endothelial dysfunction that accelerate atherosclerosis.

Cardiac remodeling begins early. Left ventricular hypertrophy is more severe in PA than in essential hypertension at equivalent blood pressure levels, according to a meta-analysis of 25 studies published in the Journal of Clinical Endocrinology & Metabolism 4. This excess myocardial mass regresses after adrenalectomy or mineralocorticoid receptor antagonist therapy, confirming that aldosterone itself drives the change.

Renal damage follows a similar pattern. PA patients show higher rates of albuminuria and a faster decline in estimated glomerular filtration rate compared to blood-pressure-matched controls 5. Aldosterone promotes perivascular fibrosis in the kidney cortex, creating a self-reinforcing cycle of sodium retention, volume expansion, and progressive nephron loss. Early detection and treatment can partially reverse this process, but prolonged exposure leaves permanent scarring.

When to Seek Medical Evaluation

Certain clinical red flags should prompt an aldosterone workup without delay. The 2016 Endocrine Society Clinical Practice Guideline lists specific screening indications, and the European Society of Hypertension endorsed similar criteria in its 2020 position statement 2.

Screen now if any of the following apply:

• Blood pressure above 150/100 mmHg on three separate measurements
• Hypertension requiring three or more drugs, or controlled only on four or more drugs (resistant hypertension)
• Hypertension with spontaneous or diuretic-induced hypokalemia (K+ <3.5 mEq/L)
• Hypertension with an adrenal incidentaloma found on CT or MRI
• Hypertension with a family history of early-onset hypertension or stroke before age 40
• Hypertension with obstructive sleep apnea (PA prevalence in this group exceeds 30% in some series)
• Any first-degree relative diagnosed with primary aldosteronism

Dr. John W. Funder, who chaired the original Endocrine Society guideline committee, stated: "The single most important message is that primary aldosteronism is common, not rare, and that the traditional reliance on hypokalemia as a screening trigger misses the majority of cases" 2.

Do not wait for potassium to drop. Do not wait for three medications to fail. If your blood pressure is persistently elevated and you are younger than 40, or if two medications have not brought your readings below 140/90 mmHg, ask your doctor about an aldosterone-to-renin ratio test.

How High Aldosterone Is Diagnosed

Diagnosis follows a three-step protocol: screen, confirm, subtype.

Step 1: The aldosterone-to-renin ratio (ARR). This blood test is the recommended initial screen. A morning sample drawn after the patient has been upright for at least 2 hours and seated for 5 to 15 minutes is standard. An ARR above 30 ng/dL per ng/mL/h with a plasma aldosterone concentration (PAC) above 15 ng/dL is considered a positive screen 2. Certain medications interfere with results. Beta-blockers suppress renin and can produce false positives. Spironolactone, eplerenone, and amiloride must be stopped at least 4 weeks before testing. ACE inhibitors and ARBs can produce false negatives but are generally acceptable to continue if stopping them would leave blood pressure dangerously uncontrolled.

Step 2: Confirmatory testing. A positive ARR alone is not diagnostic. The Endocrine Society guideline recommends one of four confirmatory tests: oral sodium loading, intravenous saline infusion, fludrocortisone suppression, or captopril challenge 2. The saline infusion test is most widely used. Two liters of 0.9% saline are infused over 4 hours; a post-infusion aldosterone above 10 ng/dL confirms autonomous aldosterone production. Values between 5 and 10 ng/dL are indeterminate.

Step 3: Subtyping. This step determines whether the aldosterone excess comes from one adrenal gland (usually an adenoma, curable with surgery) or both glands (bilateral hyperplasia, managed medically). A thin-cut adrenal CT is the first imaging step, but CT alone misclassifies the source in up to 37.8% of cases according to a study of 203 patients in the Annals of Surgery 6. Adrenal vein sampling (AVS) remains the gold standard for lateralization in patients who are surgical candidates.

The SPARTACUS trial, published in The Lancet Diabetes & Endocrinology in 2016, compared CT-based treatment decisions with AVS-guided decisions in 200 PA patients. At one year, blood pressure and quality of life outcomes were similar between groups 7. This trial shifted practice toward considering CT-only workups in younger patients (<40 years) with clear unilateral adenomas and contralateral normal glands, though most centers still recommend AVS for patients over 40.

Causes of High Aldosterone

Primary aldosteronism accounts for the vast majority of clinically significant aldosterone excess. Two subtypes dominate.

Unilateral aldosterone-producing adenoma (APA) causes 30 to 40% of PA cases. These are typically small, benign tumors (<2 cm) in one adrenal gland. Somatic mutations in potassium channel genes (KCNJ5) are found in about 40% of APAs, and KCNJ5-mutant tumors tend to be larger, more common in women, and associated with more severe hypokalemia 8. Laparoscopic adrenalectomy cures the biochemical abnormality in 94 to 99% of these patients and normalizes blood pressure without medication in approximately 37 to 42% 9.

Bilateral adrenal hyperplasia (BAH) accounts for 60 to 70% of PA cases. Both adrenal glands overproduce aldosterone, making surgery inappropriate. Medical therapy with mineralocorticoid receptor antagonists is the standard approach.

Less common causes include unilateral adrenal hyperplasia (2 to 3%), familial hyperaldosteronism types I through IV, and adrenocortical carcinoma (rare, but should be suspected with adrenal masses >4 cm or rapidly growing lesions).

Secondary hyperaldosteronism, a distinct entity, involves high aldosterone driven by high renin. Causes include renal artery stenosis, heart failure, hepatic cirrhosis, and nephrotic syndrome. The ARR is typically low or normal in secondary forms because both aldosterone and renin are elevated.

Treatment Options for High Aldosterone

Treatment depends on whether the source is unilateral or bilateral. The PASO (Primary Aldosteronism Surgical Outcome) consensus, published in The Lancet Diabetes & Endocrinology in 2017, standardized outcome reporting across 31 international centers 9.

For unilateral disease (APA or unilateral hyperplasia): Laparoscopic adrenalectomy is first-line. The PASO study reported complete biochemical success (normalized ARR and potassium without mineralocorticoid receptor antagonists) in 94% of 705 adrenalectomy patients at 6 to 12 months. Complete clinical success (blood pressure <140/90 mmHg without any antihypertensive medication) occurred in 37%. Partial clinical success (same blood pressure target on fewer medications, or reduction in systolic blood pressure by at least 20 mmHg) occurred in an additional 47%. Only 16% showed absent clinical success. Longer duration of hypertension, older age, higher BMI, and having more than two antihypertensives preoperatively predicted incomplete blood pressure resolution, emphasizing the value of early diagnosis.

For bilateral disease: Spironolactone is the first-line mineralocorticoid receptor antagonist. Starting doses of 12.5 to 25 mg daily, titrated up to 50 to 100 mg, typically normalize potassium within weeks and lower blood pressure by 20 to 25 mmHg systolic over 6 to 12 months. Side effects include breast tenderness and gynecomastia in men (reported in up to 54% at doses above 150 mg) and menstrual irregularities in premenopausal women 10.

Eplerenone offers a more selective alternative with fewer antiandrogenic side effects. It is FDA-approved for hypertension at doses of 25 to 50 mg twice daily, though it is roughly 60% as potent as spironolactone at equivalent doses and costs significantly more 11.

Dr. Michael Stowasser of the University of Queensland, a leading PA researcher, noted: "Given that primary aldosteronism is the most common cause of secondary hypertension and carries excess cardiovascular risk beyond blood pressure alone, routine screening in at-risk populations should be standard of care, not the exception" 12.

Living With High Aldosterone: Monitoring and Long-Term Outlook

Patients on mineralocorticoid receptor antagonist therapy require ongoing monitoring. Check serum potassium and creatinine at 1 month, 3 months, and every 6 to 12 months thereafter. The goal is a serum potassium of 4.0 to 5.0 mEq/L.

Dietary sodium restriction to <2 to 000 mg daily amplifies the blood pressure benefit of spironolactone. Potassium supplementation is usually unnecessary once the MRA has reached therapeutic dose, and excessive potassium intake combined with an MRA risks hyperkalemia (K+ >5.5 mEq/L), particularly in patients with reduced kidney function.

Post-adrenalectomy, patients should have blood pressure and potassium rechecked at 1, 3, and 12 months. Antihypertensive medications should be tapered gradually rather than stopped abruptly. The contralateral adrenal gland, suppressed by years of autonomous aldosterone from the adenoma, may take weeks to months to resume normal function. Transient hyperkalemia in the first few postoperative weeks is possible and may require fludrocortisone supplementation in rare cases.

Long-term cardiovascular outcomes improve substantially with treatment. A 2018 cohort study of 602 PA patients followed for a median of 11.8 years showed that both adrenalectomy and MRA therapy reduced the excess cardiovascular event rate to levels comparable with matched essential hypertension controls, provided treatment achieved blood pressure normalization 13. Patients whose blood pressure remained above target retained the excess risk, underscoring that aldosterone-specific treatment must be paired with adequate blood pressure control.

The single most important step is getting tested. If your blood pressure is difficult to control, if your potassium keeps running low, or if you have unexplained fatigue with muscle cramps, request an aldosterone-to-renin ratio from your physician.